Biomedical markers of response to intravesical BCG treatment in high-grade non-muscle invasive (PTA and PT1) transitional cell carcinoma of the bladder
Intravesical Bacillus Calmette–Guérin (BCG) immunotherapy is the main treatment for bladder high-grade non-muscle invasive transitional cell carcinoma (HGNMITCC) following initial resection. Unfortunately, about 30% of patients will not respond to treatment and they carry a high risk of disease prog...
| Main Author: | |
|---|---|
| Published: |
University of Brighton
2015
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.678922 |